Levosimendan

14 (11.6%)

2 (4.0%)

0.118

IABP insertion

21 (17.5%)

3 (6.0%)

0.049*

Superficial wound infection

11 (9.1%)

4 (8.0%)

0.806

Cerebrovascular events

6 (5.0%)

1 (2.0%)

0.369

MI

20 (16.6%)

5 (10.0%)

0.263

Non-fatal MI

13 (10.8%)

4 (8.0%)

0.574

Non-fatal cerebrovascular events

5 (4.1%)

1 (2.0%)

0.015*

Readmission for HF

5 (4.1%)

1 (2.0%)

0.015*

30-days mortality

10 (8.3%)

1 (2.0%)

0.126

Post-operative NYHA

class

I

61 (55.4%)

29 (59.2%)

II

42 (38.2%)

18 (36.7%)

0.813

III

7 (6.4%)

2 (4.1%)

Postoperative CCS grade

I

70 (63.6%)

31 (63.3%)

II

38 (34.6%)

17 (34.7%)

0.995

III

2 (1.8%)

1 (2.0%)

Postoperative LVEDD (cm)

5.67 ± 0.49

5.40 ± 0.54

0.007*

Postoperative LVESD (cm)

4.43 ± 0.68

3.44 ± 0.57

0.002*

Postoperative EF (cm)

38.98 ± 8.50

59.44 ± 6.88

<0.001*

30-days mortality

10 (8.3%)

1 (2.0%)

0.126

LIMA = left internal mammary artery, RIMA = right internal mammary artery, SV = Saphenous vein, CPB = cardiopulmonary bypass, ACC = aortic cross-clamp, DC = defibrillating cardiac, ICU = intensive care unit, IABP = intra-aortic balloon pump, MI = Myocardial infection, HF = Heart failure, NYHA = New York Heart Association, CCS = Canadian cardiovascular society, EF = ejection fraction, LVEDD = left ventricular end diastolic diameter, LVESD = left ventricular end systolic diameter.